| Views | |
|---|---|
| Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | 66 |
| December 2025 | January 2026 | February 2026 | March 2026 | April 2026 | May 2026 | June 2026 | |
|---|---|---|---|---|---|---|---|
| Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | 3 | 7 | 11 | 4 | 8 | 3 | 1 |
| Views | |
|---|---|
| Naletova_Pharmacoepidemiologic_25.pdf | 14 |
| Views | |
|---|---|
| Canada | 17 |
| United States | 14 |
| China | 2 |
| Netherlands | 2 |
| Argentina | 1 |
| Australia | 1 |
| Germany | 1 |
| United Kingdom | 1 |
| Indonesia | 1 |
| Vietnam | 1 |
| Views | |
|---|---|
| Ottawa | 16 |
| Mountain View | 3 |
| Sacramento | 3 |
| San Francisco | 3 |
| Aalsmeer | 1 |
| Amsterdam | 1 |
| Brisbane | 1 |
| Dortmund | 1 |
| Englewood | 1 |
| Guangzhou | 1 |